Reuven J. Schore

Reuven J. Schore

Pediatrics

9850 Key West Avenue
Rockville, MD 20850

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 44 publications

Early Acute Leukemia Relapse After CD19-Directed CAR-T With Lineage Switch From B to T-ALL in a Pediatric Patient.

Early Acute Leukemia Relapse After CD19-Directed CAR-T With Lineage Switch From B to T-ALL in a Pediatric Patient.

Journal: Pediatric blood & cancer

Published: May 22, 2026

Ixazomib with chemotherapy for childhood relapsed acute lymphoblastic leukemia: a TACL consortium report.

Ixazomib with chemotherapy for childhood relapsed acute lymphoblastic leukemia: a TACL consortium report.

Journal: Blood neoplasia

Published: March 03, 2026

Toxicity from asparaginase during acute lymphoblastic leukemia induction: a report from the Children's Oncology Group.

Toxicity from asparaginase during acute lymphoblastic leukemia induction: a report from the Children's Oncology Group.

Journal: Blood advances

Published: January 26, 2026

Toxicity from asparaginase during acute lymphoblastic leukemia induction: A report from the Children's Oncology Group.

Toxicity from asparaginase during acute lymphoblastic leukemia induction: A report from the Children's Oncology Group.

Journal: Blood advances

Published: January 26, 2026

Adding induction intrathecal cytarabine in newly diagnosed CNS2 B-acute lymphoblastic leukemia does not improve outcomes.

Adding induction intrathecal cytarabine in newly diagnosed CNS2 B-acute lymphoblastic leukemia does not improve outcomes.

Journal: Blood advances

Published: January 08, 2026

Chromosome 15q deletions confer inferior outcomes among children with ETV6::RUNX1 B-cell acute lymphoblastic leukemia.

Chromosome 15q deletions confer inferior outcomes among children with ETV6::RUNX1 B-cell acute lymphoblastic leukemia.

Journal: Blood advances

Published: January 07, 2026

Diminished Quality of Life Despite Reduced Treatment in Children With B-Lymphoblastic Leukemia: Children's Oncology Group AALL0932.

Diminished Quality of Life Despite Reduced Treatment in Children With B-Lymphoblastic Leukemia: Children's Oncology Group AALL0932.

Journal: Pediatric blood & cancer

Published: July 24, 2025

Molecular Risk Markers Define Risk of Relapse in Myeloid Leukemia of Down syndrome Beyond Measurable Residual Disease.

Molecular Risk Markers Define Risk of Relapse in Myeloid Leukemia of Down syndrome Beyond Measurable Residual Disease.

Journal: Blood advances

Published: July 22, 2025

Molecular risk markers define risk of relapse in myeloid leukemia of Down syndrome beyond measurable residual disease.

Molecular risk markers define risk of relapse in myeloid leukemia of Down syndrome beyond measurable residual disease.

Journal: Blood advances

Published: July 22, 2025

Caregivers' Perspectives on Changes in Family Life During B-ALL Therapy: A Qualitative Study From the Children's Oncology Group.

Caregivers' Perspectives on Changes in Family Life During B-ALL Therapy: A Qualitative Study From the Children's Oncology Group.

Journal: Pediatric blood & cancer

Published: May 27, 2025

Vincristine Sulfate Liposome Injection With Combination Chemotherapy for Children, Adolescents, and Young Adults With Relapsed Acute Lymphoblastic Leukemia: A Therapeutic Advances in Childhood Leukemia and Lymphoma Consortium Trial.

Vincristine Sulfate Liposome Injection With Combination Chemotherapy for Children, Adolescents, and Young Adults With Relapsed Acute Lymphoblastic Leukemia: A Therapeutic Advances in Childhood Leukemia and Lymphoma Consortium Trial.

Journal: Pediatric blood & cancer

Published: December 09, 2024

Heterogeneity of IKZF1 genomic alterations and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia.

Heterogeneity of IKZF1 genomic alterations and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia.

Journal: Research square

Published: November 28, 2024

Showing 1-12 of 44

Last Updated: 09/26/2026